论文部分内容阅读
奥曲肽(Octreotide,OCT)是一种生长抑素类似物,与后者相比,其具有作用强、半衰期长和不影响糖代谢之优点,本文就OCT对术后小肠瘘出量的影响,进行了随机双盲交叉试验。方法:将已用保守治疗如胃肠外营养、西米替丁等的14例术后小肠瘘病人随机分成两组。Ⅰ组(8例):先给予OCT治疗2天然后改用安慰剂治疗2天;Ⅱ组(6例):先给予安慰剂治疗2天,然后改用OCT治疗2天。所有病人经4天试验后继续服用OCT直至瘘口闭合或再手术。OCT给药方法为每次皮下注射0.075～0.100 mg,每8小时1
Octreotide (OCT) is an analog of somatostatin, which has the advantages of strong effect, long half-life and no effect on glucose metabolism compared with the latter. In this paper, the effect of OCT on the output of postoperative small intestinal fistula A randomized double-blind crossover test. METHODS: Fourteen patients with postoperative intestinal fistula that had been treated conservatively, such as parenteral nutrition and cimetidine, were randomized into two groups. Group Ⅰ (n = 8) received OCT for 2 days and placebo for 2 days. Group Ⅱ (n = 6) received placebo for 2 days and then OCT for 2 days. All patients continued OCT after 4 days of testing until the fistula closed or reoperated. The method of OCT administration is 0.075 ~ 0.100 mg subcutaneously every 1 hour every 8 hours